Source : University of Calgary
A new study found that nirsevimab, an immunization designed to protect infants from severe RSV, reduced RSV-related hospitalizations by 79% and intensive care admissions by 97%. The research analyzed infants treated at seven pediatric hospitals in Ontario and Quebec during the 2024–2025 RSV season.